News

A new therapy is being evaluated for the treatment of dry age-related macular degeneration.

No definitive medical or surgical treatments for nonarteritic anterior ischemic optic neuropathy (NAION) have emerged following years of research.

In a multicenter trial evaluating the outcomes following vitrectomy for diabetic macular edema, investigators with the Diabetic Retinopathy Clinical Research Network found that visual acuity improvement was associated with the removal of epiretinal membrane during surgery and worse baseline VA.

When the ophthalmology department at Weill Cornell Medical College, New York, was looking for an image management system that could integrate with the existing electronic medical record system, four vendors were invited to showcase their products to the selection committee.

While conversing with a group of professors during a recent dinner at an ophthalmology meeting, it occurred to the author that the people sitting around the table represented four continents. As the lone American, he felt his colleagues may be able to offer a message to ophthalmologists in the United States.

With the advent of intravitreal agents that block the negative effects of vascular endothelial growth factor among patients with age-related macular degeneration, ophthalmologists have begun to seek a higher level of performance from their diagnostic equipment.

Analyses exploring relationships between structural and functional losses in glaucoma show that early structural damage as measured by spectral-domain optical coherence tomography can occur in the absence of visual field changes.

Retinal nerve fiber layer measurements may be a surrogate marker of axonal damage of the anterior visual pathway that will enhance understanding of mechanisms of optic nerve damage.

Fourier-domain optical coherence tomography and time-domain OCT have both showed that the retinal nerve fiber layer is significantly thinner in glaucomatous eyes.

An anti-platelet-derived growth factor aptamer is safe and well-tolerated when used in combination with anti-vascular endothelial growth factor therapy in patients with neovascular age-related macular degeneration.

Choroidal thinning is not a feature of glaucoma nor does choroidal thickness correlate with retinal nerve fiber layer thickness, according to new study findings.

The Association for Research in Vision and Ophthalmology and the ARVO Foundation for Eye Research will honor awards recipients at the 2010 annual meeting's ARVO/Alcon keynote session in May.

A dispensing ophthalmologist is part of a large, highly competitive retail environment. Your retail competition uses research that you might be ignoring to woo patients away from your on-site optical shop.

Vision Expo is maturing as a meeting and the staffs have been making steady improvements in show management.

Eyes categorized as having keratoconus based on corneal topography and subsequently determined to be non-keratoconic by epithelial thickness profile criteria demonstrate good refractive stability after LASIK during up to 2 years of follow-up.

A user-friendly diagnostic ultrasound device offers a range of features that makes it a valuable instrument for anterior and posterior ophthalmic imaging both for clinical use and for teaching applications.

Studies conducted with waveform data obtained using a non-contact applanation tonometer show that this information pertaining to corneal biomechanical properties may have value in helping to identify early-stage compromised corneas.

Medical therapy for glaucoma is the first option for most patients in developed countries, according to one expert.

As members of the healthcare industry try to unravel the comprehensive health reform legislation that President Obama signed into law March 23, they are voicing concerns about such issues as patient access, payment for physicians, the creation of a new oversight board, and new taxes on medical devices.

Ludwin Monz, PhD, MBA, is the new chief executive officer of Carl Zeiss Meditec AG, succeeding Michael Kaschke, PhD, who now is chairman and a member of the company?s supervisory board.

The FDA has accepted the filing of Lux Biosciences? new drug application for oral voclosporin (Luveniq) and has granted the application priority review, according to the company.

Acucela Inc. and Otsuka Pharmaceutical Co. Ltd. have received fast-track designation from the FDA for ACU-4429, an investigational oral treatment for dry age-related macular degeneration.

The FDA has accepted for review the supplemental new drug application (sNDA) of ISTA Pharmaceuticals Inc. for once-daily bromfenac ophthalmic solution (XiDay).

Alcon Laboratories Inc. has received regulatory approval and finalized the acquisition of the rights in the United States for difluprednate ophthalmic emulsion 0.05% emulsion (Durezol) and the global rights, excluding Latin America, for cyclosporine (Zyclorin) from Sirion Therapeutics Inc. Alcon immediately assumed responsibility for all marketing, promotion, and sales of the difluprednate formulation.

Haag-Streit USA has appointed Alcon Laboratories Inc. as its exclusive distributor in the United States for an optical biometer (Lenstar LS900).

Aton Pharma Inc. has launched an authorized generic version of its timolol maleate ophthalmic gel-forming solution (Timoptic-XE). The non-selective beta-adrenergic receptor blocking agent is indicated in the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma. The company also will continue to make available timolol maleate under the brand name.

Bausch + Lomb has relaunched its multipurpose contact lens solution (renu fresh) in a clear bottle designed to enable users to see exactly how much solution is remaining.

Physicians who see patients thought they were getting another 30-day reprieve in a planned 21.2% pay cut. Instead, as of March 1, the cut will take effect.

Bausch + Lomb, with a foundation built on a "legendary" 157-year-old brand, is poised for growth, according to its CEO.

Highlighting the many developments in the area of oculogenetics, Edwin M. Stone, MD, PhD, is concentrating on a gene therapy experiment.